Merck Shares Outstanding 2010-2024 | MRK
Merck shares outstanding history from 2010 to 2024. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
- Merck shares outstanding for the quarter ending September 30, 2024 were 2.541B, a 0.2% decline year-over-year.
- Merck 2023 shares outstanding were 2.547B, a 0.2% increase from 2022.
- Merck 2022 shares outstanding were 2.542B, a 0.16% increase from 2021.
- Merck 2021 shares outstanding were 2.538B, a 0.12% decline from 2020.
Merck Annual Shares Outstanding
(Millions of Shares) |
| 2023 |
2,547 |
| 2022 |
2,542 |
| 2021 |
2,538 |
| 2020 |
2,541 |
| 2019 |
2,580 |
| 2018 |
2,679 |
| 2017 |
2,748 |
| 2016 |
2,787 |
| 2015 |
2,841 |
| 2014 |
2,928 |
| 2013 |
2,996 |
| 2012 |
3,076 |
| 2011 |
3,094 |
| 2010 |
3,120 |
| 2009 |
2,273 |
Merck Quarterly Shares Outstanding
(Millions of Shares) |
| 2024-09-30 |
2,541 |
| 2024-06-30 |
2,544 |
| 2024-03-31 |
2,544 |
| 2023-12-31 |
2,547 |
| 2023-09-30 |
2,546 |
| 2023-06-30 |
2,539 |
| 2023-03-31 |
2,551 |
| 2022-12-31 |
2,542 |
| 2022-09-30 |
2,542 |
| 2022-06-30 |
2,540 |
| 2022-03-31 |
2,537 |
| 2021-12-31 |
2,538 |
| 2021-09-30 |
2,536 |
| 2021-06-30 |
2,540 |
| 2021-03-31 |
2,541 |
| 2020-12-31 |
2,541 |
| 2020-09-30 |
2,538 |
| 2020-06-30 |
2,536 |
| 2020-03-31 |
2,547 |
| 2019-12-31 |
2,580 |
| 2019-09-30 |
2,572 |
| 2019-06-30 |
2,588 |
| 2019-03-31 |
2,603 |
| 2018-12-31 |
2,679 |
| 2018-09-30 |
2,678 |
| 2018-06-30 |
2,696 |
| 2018-03-31 |
2,710 |
| 2017-12-31 |
2,748 |
| 2017-09-30 |
2,727 |
| 2017-06-30 |
2,752 |
| 2017-03-31 |
2,766 |
| 2016-12-31 |
2,787 |
| 2016-09-30 |
2,786 |
| 2016-06-30 |
2,789 |
| 2016-03-31 |
2,795 |
| 2015-12-31 |
2,841 |
| 2015-09-30 |
2,836 |
| 2015-06-30 |
2,850 |
| 2015-03-31 |
2,865 |
| 2014-12-31 |
2,928 |
| 2014-09-30 |
2,911 |
| 2014-06-30 |
2,949 |
| 2014-03-31 |
2,971 |
| 2013-12-31 |
2,996 |
| 2013-09-30 |
2,960 |
| 2013-06-30 |
3,010 |
| 2013-03-31 |
3,053 |
| 2012-12-31 |
3,076 |
| 2012-09-30 |
3,079 |
| 2012-06-30 |
3,072 |
| 2012-03-31 |
3,074 |
| 2011-12-31 |
3,094 |
| 2011-09-30 |
3,091 |
| 2011-06-30 |
3,110 |
| 2011-03-31 |
3,104 |
| 2010-12-31 |
3,120 |
| 2010-09-30 |
3,102 |
| 2010-06-30 |
3,125 |
| 2010-03-31 |
3,141 |
| 2009-12-31 |
2,273 |
| 2009-09-30 |
2,114 |
| 2009-06-30 |
2,110 |
| 2009-03-31 |
2,109 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$244.211B |
$60.115B |
|
Merck & Co. boasts more than six blockbuster drugs in its portfolio with PD-L1 inhibitor, Keytruda, approved for several types of cancer. Keytruda has played an instrumental role in driving Merck's steady revenue growth in the past few years. Well-known products in Merck's portfolio include Keytruda, Simponi , Januvia and Janumet, Bridion, Isentress, ProQuad, Gardasil, Pneumovax 23, RotaTeq and Belsomra. Merck made its biggest acquisition of Schering-Plough and sold off its Consumer Care business to Bayer. Other key acquisitions include Idenix Pharmaceuticals, Cubist Pharmaceuticals, Rigontec, ArQule and Acceleron Pharma. IMerck spun off products from its Women's Health unit, legacy drugs and biosimilar products into a new publicly traded company called Organon & Co.
|
